<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25834" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neurosarcoidosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pirau</surname>
            <given-names>Letitia</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lui</surname>
            <given-names>Forshing</given-names>
          </name>
          <aff>CA Northstate Uni, College of Med</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Letitia Pirau declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Forshing Lui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25834.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Sarcoidosis is a systemic disease that results in the formation of granulomas which classically are non-caseating granulomas, that may be found throughout lymph nodes and organs, including the brain and nervous system. About 5 to 10 percent of patients with sarcoidosis will have neurologic complications. Neurosarcoidosis may be asymptomatic but can be life-threatening and tends to occur in cases with systemic involvement. This activity examines when this condition should be considered on differential diagnosis and how to properly evaluate for it. This activity highlights the role of the interprofessional team in caring for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the common presenting features of neurosarcoidosis.</p></list-item><list-item><p>Review how to properly evaluate for neurosarcoidosis.</p></list-item><list-item><p>Outline the management of neurosarcoidosis.</p></list-item><list-item><p>Explain how an interprofessional approach is imperative to the effective management of patients with neurosarcoidosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25834&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25834">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25834.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Although the etiology is unknown, sarcoidosis is a systemic disease that results in the formation of granulomas. Classically, the granulomas in sarcoidosis are non-caseating granulomas,&#x000a0;which may be found&#x000a0;throughout lymph nodes and organs, including the brain and nervous system. About 5% to 10% of patients with sarcoidosis will have neurologic complications.<xref ref-type="bibr" rid="article-25834.r1">[1]</xref><xref ref-type="bibr" rid="article-25834.r2">[2]</xref> Although&#x000a0;the majority of&#x000a0;patients with sarcoidosis do not have symptoms,&#x000a0;neurosarcoidosis&#x000a0;may be life-threatening and&#x000a0;tends to occur&#x000a0;in cases with systemic involvement.</p>
        <p>Neurosarcoidosis tends to occur in patients who have systemic features and active disease. The diagnosis of neurosarcoidosis is difficult and usually one of exclusion. Sometimes a nerve or muscle biopsy may reveal a non-caseating granuloma. There is no cure for neurosarcoidosis. Most patients require long-term treatment with corticosteroids.</p>
      </sec>
      <sec id="article-25834.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Although the cause is unclear,&#x000a0;sarcoidosis is believed&#x000a0;to be a hyperactive immune response. Th1 cells stimulate the release of IL-2 and IFN-gamma which then activate macrophages.&#x000a0;In turn, the&#x000a0;inflammatory response induced by macrophages causes granuloma formation. The most common neurological abnormalities reported include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Papilledema</p>
          </list-item>
          <list-item>
            <p>Cranial neuropathies</p>
          </list-item>
          <list-item>
            <p>Peripheral neuropathy</p>
          </list-item>
          <list-item>
            <p>Myopathy and mononeuropathy</p>
          </list-item>
          <list-item>
            <p>Neuropsychiatric disturbances</p>
          </list-item>
          <list-item>
            <p>Ataxia</p>
          </list-item>
          <list-item>
            <p>Hydrocephalus</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25834.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of sarcoidosis has been estimated&#x000a0;to be about 152 to 215 per 100,000.<xref ref-type="bibr" rid="article-25834.r3">[3]</xref>&#x000a0;About 5 to 10% of patients with sarcoidosis will have neurologic complications.<xref ref-type="bibr" rid="article-25834.r1">[1]</xref>&#x000a0;Regarding race,&#x000a0;neurosarcoidosis&#x000a0;has&#x000a0;been documented&#x000a0;more commonly within Africans and African descent.<xref ref-type="bibr" rid="article-25834.r4">[4]</xref>&#x000a0;However, about half of patients with sarcoidosis have systemic disease, with 30% to 70% who have concomitant neurologic signs when first diagnosed. The condition is rare in children.</p>
      </sec>
      <sec id="article-25834.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>A variety of theories have been used&#x000a0;to explain the etiology of&#x000a0;neurosarcoidosis. Sarcoidosis affects the lymphoreticular system, characterized by cervical and mediastinal lymphadenopathy.&#x000a0; Due to&#x000a0;the distribution of lymphatics, the spleen and liver can also&#x000a0;be&#x000a0;affected.&#x000a0;Neurosarcoidosis&#x000a0;results from sarcoid granulomas within the nervous system. Pathologically, lymphocytes and mononuclear phagocytes surround a noncaseating epithelioid cell granuloma. Symptoms result from the location of where the granulomas lie in the nervous system. For example, granulomas in the muscle may cause myositis, while granulomas in the nerve within the perineurium and epineurium may cause axonal damage and as a result peripheral neuropathy. Nerve injury may cause diffuse polyneuropathy,&#x000a0;mononeuritis&#x000a0;multiplex, and polyradiculopathy&#x000a0;due to spinal root sheath involvement.</p>
      </sec>
      <sec id="article-25834.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The classical finding of sarcoidosis is noncaseating granulomas. Nerve biopsies&#x000a0;demonstrate&#x000a0;axonal degeneration with nerve atrophy.&#x000a0;Myelin ovoids may be seen&#x000a0;as a sign of demyelination.<xref ref-type="bibr" rid="article-25834.r5">[5]</xref></p>
      </sec>
      <sec id="article-25834.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Common features of central or peripheral nervous system involvement include cranial mononeuropathy involving the facial nerve, neuroendocrine dysfunction involving the hypothalamus (i.e. neurogenic diabetes insipidus), myelopathy or radiculopathy if the spinal cord&#x000a0;is affected&#x000a0;(in rare cases cauda equina&#x000a0;polyradiculopathy&#x000a0;may occur), hydrocephalus, meningitis, mononeuropathy,&#x000a0;mononeuritis&#x000a0;multiplex, carpal tunnel, and muscle involvement which may cause proximal myopathy and muscle atrophy. Symptoms of&#x000a0;neurosarcoidosis&#x000a0;may be multifocal, commonly seen first in the cranial nerves. The facial nerve is the most common cranial nerve affected, which may mimic Lyme disease.&#x000a0;Heerfordt&#x000a0;syndrome is a rare manifestation of&#x000a0;neurosarcoidosis&#x000a0;which presents with facial nerve palsy and&#x000a0;the presence of&#x000a0;parotid gland enlargement, anterior uveitis, and fever.<xref ref-type="bibr" rid="article-25834.r6">[6]</xref>&#x000a0;Carpal tunnel may also be more frequent in sarcoidosis patients than in the rest of the population.<xref ref-type="bibr" rid="article-25834.r7">[7]</xref>&#x000a0;Another cranial nerve that may&#x000a0;be affected&#x000a0;is the&#x000a0;vestibulocochlear&#x000a0;nerve causing balance and hearing problems.<xref ref-type="bibr" rid="article-25834.r8">[8]</xref>&#x000a0;Cerebellar signs, such as ataxia, may be present with cerebellar involvement.<xref ref-type="bibr" rid="article-25834.r9">[9]</xref>&#x000a0;During the exam, it is important to assess for papilledema and mental status as psychiatric abnormalities may also occur.&#x000a0;Chronic meningitis with basal meningeal involvement is a common manifestation of neurosarcoidosis. Meningitis may present with either leptomeningeal or pachymeningeal involvement. It is one of the several important causes of pachymeningitis.</p>
        <p>In gathering a history, the first sign of&#x000a0;neurosarcoidosis&#x000a0;may be seizures, which&#x000a0;generally&#x000a0;confers a poor prognosis. Patients with simple partial or complex partial seizures may have a better prognosis&#x000a0;in comparison&#x000a0;to generalized tonic-clonic seizures.</p>
        <p>Depending on the location of the disease in the brain, the patient may also present with:</p>
        <list list-type="bullet">
          <list-item>
            <p>Syndrome of inappropriate secretion of antidiuretic hormone (SIADH)</p>
          </list-item>
          <list-item>
            <p>Changes in appetite</p>
          </list-item>
          <list-item>
            <p>Somnolence</p>
          </list-item>
          <list-item>
            <p>Autonomic impairment</p>
          </list-item>
          <list-item>
            <p>Weight gain</p>
          </list-item>
          <list-item>
            <p>Impotence</p>
          </list-item>
          <list-item>
            <p>Galactorrhea</p>
          </list-item>
          <list-item>
            <p>Dementia</p>
          </list-item>
          <list-item>
            <p>Impaired cognition</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25834.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Neurosarcoidosis&#x000a0;should be&#x000a0;considered&#x000a0;in patients with sarcoidosis who develop neurologic abnormalities. However, the index of suspicion is lower and thus much more difficult&#x000a0;in cases&#x000a0;where a patient&#x000a0;is not known&#x000a0;to have sarcoid but has neurologic abnormalities.&#x000a0;Unfortunately, there is no diagnostic marker for&#x000a0;neurosarcoidosis.&#x000a0;</p>
        <p>If&#x000a0;neurosarcoidosis&#x000a0;is&#x000a0;suspected, it&#x000a0;is important to assess for signs of systemic&#x000a0;diseases, such as the skin, lymph nodes, and lungs. Tests to conduct include&#x000a0;ophthalmologic exam (including optical coherence tomography), nasal/sinus examination, chest x-ray (for&#x000a0;perihilar&#x000a0;lymphadenopathy), angiotensin-converting enzyme (ACE) assay (not specific), and in rare cases a magnetic resonance, gallium or&#x000a0;fluorodeoxyglucose&#x000a0;emission tomographic scan for areas of inflammation that may&#x000a0;be biopsied.</p>
        <p>In&#x000a0;evaluating&#x000a0;peripheral neuropathy, it is important to rule out other common causes of neuropathy such as hyperglycemic states, vitamin deficiencies, kidney failure, and toxins.&#x000a0;Thermal threshold testing may be used&#x000a0;for small-fiber neuropathy.</p>
        <p>Neurodiagnostic&#x000a0;tests may help rule out other differentials such as infection and malignancy. The imaging of choice is a&#x000a0;contrast-enhanced&#x000a0;MRI. Typical findings are basal meningeal enhancement especially with contrast-enhancing lesions involving the hypothalamus, pituitary stalk, and adjacent tissues. (See MRI below). Gadolinium and&#x000a0;fluid-attenuated&#x000a0;inversion recovery (FLAIR) are helpful to identify T2 enhancement of nerve roots, plexuses, and nerves.&#x000a0;Active inflammation may be seen&#x000a0;with meningeal or parenchymal enhancement.&#x000a0;Parenchymal, meningeal masses, and hydrocephalus may also be seen&#x000a0;with MRI.&#x000a0;</p>
        <p>As with other inflammatory states,&#x000a0;ESR may be elevated.&#x000a0;Creatinine kinase and aldolase may also be used&#x000a0;to evaluate for myopathy. Liver function testing may also be abnormal,&#x000a0;thereby&#x000a0;reflecting the systemic involvement of sarcoidosis.&#x000a0;If&#x000a0;the pituitary-hypothalamic axis is affected,&#x000a0;endocrine studies should be done. In recent years, F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) imaging has been used to evaluate for neurosarcoidosis. F-18 FDG PET/CT is gaining popularity in patients with suspected systemic sarcoidosis, especially with pulmonary or cardiac involvement. It can provide valuable information to the site of involvement by the disease and the selection of more surgically accessible sites for biopsy.</p>
        <p>If the diagnosis remains uncertain, biopsies of the meninges, brain, or spinal cord may be&#x000a0;indicated.<xref ref-type="bibr" rid="article-25834.r10">[10]</xref>&#x000a0;However, biopsies of the skin, lymph node, and&#x000a0;lung are less risky and thus, are more preferred.&#x000a0;A biopsy&#x000a0;may also be considered&#x000a0;for patients who do not respond to therapy.</p>
      </sec>
      <sec id="article-25834.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Given the inflammatory process, corticosteroids are the main treatment for neural sarcoidosis. For facial nerve palsy or aseptic meningitis, prednisone&#x000a0;is given&#x000a0;every day for 2 weeks usually. In cases of meningeal, parenchymal mass lesion, or myopathy or&#x000a0;neuropathy, prednisone should be given&#x000a0;for at least 4 weeks. For deteriorating patients, intravenous (IV) methylprednisolone is given&#x000a0;for 3 days followed by prednisone for 2 to 4 weeks.&#x000a0;The steroid dose should be tapered&#x000a0;over several months with follow-up by a neurologist every 3 to 6 months.</p>
        <p>Immunosuppressants&#x000a0;may also be considered, such as cyclosporine, methotrexate, and cyclophosphamide.</p>
        <p>Low dose radiation is often given to patients in who steroids fail to work. Other treatments include:</p>
        <p>Hormone replacement if there is hypopituitarism</p>
        <p>Antipsychotics for behavior control and psychosis</p>
        <p>Support for dementia</p>
        <p>Recently tumor necrosis factor antagonists have been tried with partial improvement.</p>
      </sec>
      <sec id="article-25834.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Other differentials to consider for&#x000a0;neurosarcoidosis&#x000a0;include primary brain tumors, toxin ingestion, neuropathies secondary to monoclonal proliferation or&#x000a0;paraproteinemic&#x000a0;neuropathy, paraneoplastic neuropathy, vitamin deficiency, leptomeningeal carcinomatosis, multiple sclerosis, central nervous system (CNS) lymphoma, or autoimmune conditions like systemic lupus erythematosus.</p>
      </sec>
      <sec id="article-25834.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Neurosarcoidosis&#x000a0;may present as either a monophasic illness, a relapsing-remitting course, or as a progressive&#x000a0;disease with episodes of deterioration.&#x000a0;It&#x000a0;is not well known&#x000a0;what the&#x000a0;long-term&#x000a0;effects&#x000a0;of&#x000a0;neurosarcoidosis&#x000a0;are. Usually, patients with facial nerve palsy or other cranial mononeuropathies will improve. In contrast, cases with aseptic meningitis or meningeal/parenchymal mass lesions have a longer course. Hypothalamic vegetative symptoms rarely resolve although may respond to treatment.</p>
        <p>Encephalopathy/vasculopathy&#x000a0;tends&#x000a0;to&#x000a0;have a relapsing-remitting course with deterioration. Cases with hydrocephalus may either be asymptomatic or cause rapid deterioration. Facial palsy tends to improve over 4-6 weeks. The optic neuropathy may improve over a few weeks but in others, it may lead to blindness. Remissions are possible in peripheral neuropathy and myopathy cases,&#x000a0;however, the course usually is chronic and progressive.</p>
      </sec>
      <sec id="article-25834.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>With a diagnosis of sarcoidosis, physicians should be careful to monitor the signs and symptoms of&#x000a0;neurosarcoidosis, with the most common symptom being cranial neuropathy involving the facial nerve. However, although most cases&#x000a0;resolve,&#x000a0;it is important to provide&#x000a0;follow-up&#x000a0;care to monitor for evolving symptoms. Treatment involves steroids to stop the inflammatory response caused by systemic sarcoidosis.</p>
      </sec>
      <sec id="article-25834.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional approach to neurosarcoidosis is recommended.</p>
        <p>Cases of&#x000a0;neurosarcoidosis&#x000a0;require an interprofessional effort because the disorder has diverse presentations and has no specific test to make a diagnosis. Given the systemic involvement associated with&#x000a0;neurosarcoidosis,&#x000a0;a variety of specialists should be consulted&#x000a0;such as rheumatology, endocrinology, and pulmonology.&#x000a0;Neurosurgery may be consulted&#x000a0;as well for resection of CNS masses. However, biopsy/excision procedures that involve the CNS can be associated with severe consequences, and remain a treatment of last choice. Thus, resection should&#x000a0;be deferred, unless the mass continues to enlarge after immunosuppression. For cases with hydrocephalus, a&#x000a0;ventriculoperitoneal&#x000a0;shunt may be placed, albeit the risk of infection. Patients on prolonged steroids may benefit from a dietician consult to manage weight&#x000a0;gain&#x000a0;and&#x000a0;to develop an exercise program and reduce bone loss. All patients started on corticosteroids need to be monitored for adverse effects by the pharmacist. As soon as symptoms subside, rapid tapering of the drug is recommended.<xref ref-type="bibr" rid="article-25834.r11">[11]</xref></p>
      </sec>
      <sec id="article-25834.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25834&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25834">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/neurosarcoidosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25834">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25834/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25834">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25834.s15">
        <title>References</title>
        <ref id="article-25834.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burns</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Neurosarcoidosis.</article-title>
            <source>Arch Neurol</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>8</issue>
            <fpage>1166</fpage>
            <page-range>1166-8</page-range>
            <pub-id pub-id-type="pmid">12925378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25834.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stern</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johns</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nissim</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis and its neurological manifestations.</article-title>
            <source>Arch Neurol</source>
            <year>1985</year>
            <month>Sep</month>
            <volume>42</volume>
            <issue>9</issue>
            <fpage>909</fpage>
            <page-range>909-17</page-range>
            <pub-id pub-id-type="pmid">3896208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25834.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arkema</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Grunewald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kullberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eklund</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Askling</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden.</article-title>
            <source>Eur Respir J</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>1690</fpage>
            <page-range>1690-1699</page-range>
            <pub-id pub-id-type="pmid">27471207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25834.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacomis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Neurosarcoidosis.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>429</fpage>
            <page-range>429-36</page-range>
            <pub-id pub-id-type="pmid">22379457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25834.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nemni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Galassi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hays</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bressman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gamboa</surname>
                <given-names>ET</given-names>
              </name>
            </person-group>
            <article-title>Symmetric sarcoid polyneuropathy: analysis of a sural nerve biopsy.</article-title>
            <source>Neurology</source>
            <year>1981</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>10</issue>
            <fpage>1217</fpage>
            <page-range>1217-23</page-range>
            <pub-id pub-id-type="pmid">6287346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25834.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denny</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Fotino</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>The Heerfordt-Waldenstr&#x000f6;m syndrome as an initial presentation of sarcoidosis.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>390</fpage>
            <page-range>390-2</page-range>
            <pub-id pub-id-type="pmid">24082416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25834.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niemer</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Bolster</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Buxbaum</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Carpal tunnel syndrome in sarcoidosis.</article-title>
            <source>Sarcoidosis Vasc Diffuse Lung Dis</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>296</fpage>
            <page-range>296-300</page-range>
            <pub-id pub-id-type="pmid">11587102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25834.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colvin</surname>
                <given-names>IB</given-names>
              </name>
            </person-group>
            <article-title>Audiovestibular manifestations of sarcoidosis: a review of the literature.</article-title>
            <source>Laryngoscope</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>116</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-82</page-range>
            <pub-id pub-id-type="pmid">16481814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25834.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reda</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Boes</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>A case of sensory ataxia as the presenting manifestation of neurosarcoidosis.</article-title>
            <source>Muscle Nerve</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>900</fpage>
            <page-range>900-5</page-range>
            <pub-id pub-id-type="pmid">21607973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25834.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peeples</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Jiji</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sahni</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Germ cell tumors masquerading as central nervous system sarcoidosis.</article-title>
            <source>Arch Neurol</source>
            <year>1991</year>
            <month>May</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>554</fpage>
            <page-range>554-6</page-range>
            <pub-id pub-id-type="pmid">1850595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25834.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tana</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wegener</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Borys</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pambuccian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tchernev</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giamberardino</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Silingardi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Challenges in the diagnosis and treatment of neurosarcoidosis.</article-title>
            <source>Ann Med</source>
            <year>2015</year>
            <volume>47</volume>
            <issue>7</issue>
            <fpage>576</fpage>
            <page-range>576-91</page-range>
            <pub-id pub-id-type="pmid">26469296</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
